This edition presents key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase III study of AbbVie/Roche’s Venclexta/Venclyxto (venetoclax) in combination with Rituxan/MabThera (rituximab; Roche) presented at the ASH meeting in December 2017; the initiation of a Phase III study investigating BeiGene’s novel Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory CLL; Phase I/II results for Juno Therapeutics/Celgene’s JCAR014; and pilot trial results for an anti-CD19 CAR-T cell therapy in combination with Imbruvica (ibrutinib; Janssen Biotech/AbbVie) in patients with high-risk CLL.
- In light of the positive results for Venclexta/Rituxan in the MURANO study, do KOLs envisage any changes to the second-line treatment regimen for CLL?
- Do KOLs think it will be possible to overcome the side effects associated with the use of Venclexta/Rituxan?
- If Venclexta/Rituxan is approved for treating patients with relapsed/refractory CLL, how widespread will its use become and why?
- Will zanubrutinib’s selectivity for BTK inhibition translate into a clinically meaningful benefit for patients with CLL?
- What role will zanubrutinib play within the CLL setting, if approved, and how well will it compete with other BTK inhibitors?
- Will the toxicity associated with the use of anti-CD19 CAR-T cells confine their role to one of salvage therapy for CLL?
- Do KOLs think that combining anti-CD19 CAR-T cells with Imbruvica will provide any therapeutic advantages for patients with CLL?
- Apart from CD19, are there any other molecules which can be identified by KOLs as potentially effective therapeutic targets for CAR-T cell therapy?